Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2.52 ^USD	-0.40%		+2.02%	-59.02%

Feb. 27	Sector Update: Health Care Stocks Ease Late Afternoon	MT
Feb. 27	Top Midday Decliners	MT

MINERVA NEUROSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

May 29, 2020 at 04:28 pm EDT

Item 8.01 Other Events.

On May 29, 2020, Minerva Neurosciences, Inc. (the "Company") issued a press release providing details of the Company's results from a Phase 3 trial of roluperidone (MIN-101) for the treatment of negative symptoms in schizophrenia. A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits




(d)   Exhibits



        Exhibit No.                       Description

        99.1            Press Release of the Company dated May 29, 2020.

--------------------------------------------------------------------------------

Latest news about Minerva Neurosciences, Inc.

Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 27	MT
Top Midday Decliners	Feb. 27	MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon	Feb. 27	MT
Minerva Neurosciences Shares Tumble After FDA Rejects Roluperidone for Schizophrenia.	Feb. 27	MT
Minerva Neurosciences Shares Slide on Latest FDA Roluperidone Setback	Feb. 27	DJ
FDA Turns Away Minerva's Roluperidone Schizophrenia Drug	Feb. 27	DJ
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia	Feb. 27	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
HC Wainwright Adjusts Price Target on Minerva Neurosciences to $11 From $8, Maintains Neutral Rating	23-08-02	MT
Minerva Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01	CI
Sector Update: Health Care Stocks Declining Late Wednesday	23-06-28	MT
Sector Update: Health Care	23-06-28	MT
Top Midday Gainers	23-06-28	MT
Minerva Neurosciences to Raise $20 Million Through Private Placement of Common Shares	23-06-28	MT
Minerva Neurosciences, Inc. announced that it expects to receive $19.999994 million in funding	23-06-26	CI
Transcript : Minerva Neurosciences, Inc., Q1 2023 Earnings Call, May 15, 2023	23-05-15
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Hopes Build for -3-	23-05-15	DJ
Minerva Neurosciences Says US FDA Accepts Filing of New Drug Application for Roluperidone to Treat Schizophrenia Symptoms	23-05-10	MT
Minerva Neurosciences Gets FDA Confirmation for NDA for Roluperidone	23-05-10	DJ
Minerva Neurosciences, Inc. Announces Board Changes	23-05-05	CI
Top Midday Gainers	23-05-01	MT
FDA Files Minerva Neurosciences's NDA for Roluperidone to Treat Schizophrenia Symptoms; Shares Jump 61% Midday	23-05-01	MT

Chart Minerva Neurosciences, Inc.

Duration

Period

More charts

Company Profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.52 USD

Average target price

11 USD

Spread / Average Target

+336.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MINERVA NEUROSCIENCES, INC.	-59.02%	17.62M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs